Presented By James Rubenstein at 2016 ASCO Annual Meeting

Slides:

Advertisements

Similar presentations

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.

Advertisements

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Presented By Raymond Huang at 2014 ASCO Annual Meeting

Phase Difference = Phase Difference = 0.05.

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.

The Role of mTOR in Cancer Etiology and Treatment Based on presentations from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.

Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.

Randomized Phase III US/Canadian Intergroup Trial (SWOG S9704) Comparing CHOP ± R for Eight Cycles to CHOP ± R for Six Cycles Followed by Autotransplant.

Future directions: Can we improve outcomes in relapsed/refractory DLBCL or aggressive NHL? Bertrand Coiffier Service d’Hématologie Hospices Civils de Lyon.

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

Highlights of the Day III Genitourinary (Nonprostate) Cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting.

Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.

CCO Independent Conference Highlights

CCO Independent Conference Highlights

Presented By Michele Cavo at 2016 ASCO Annual Meeting

Presented By Sham Mailankody at 2016 ASCO Annual Meeting

Presented By Lorenz Trumper at 2016 ASCO Annual Meeting

A cura di Filippo de Marinis

NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma

Lenalidomide Shows Promising Activity in Recurrent CNS Lymphoma

Securing the cure in resectable lung cancer

REMARC: Lenalidomide vs Placebo as Maintenance Therapy in Patients With DLBCL Following R-CHOP Induction New Findings in Hematology: Independent Conference.

Highlights: Myeloma Oral Session

Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study1 Phase I Study of Rituximab,

Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Poorer Outcomes With Rituximab + Chemo in Heavier Patients, Older Men With Follicular Lymphoma CCO Independent Conference Highlights of the 2015 ASCO Annual.

Presented By Luca Malorni at 2017 ASCO Annual Meeting

continued on next slide

Presented By Jason Fangusaro at 2017 ASCO Annual Meeting

Presented By Amrita Krishnan at 2016 ASCO Annual Meeting

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Innovations and Issues in Mantle Cell Lymphoma

Relapsed/Refractory Follicular Lymphoma Conundrums

continued on next slide

continued on next slide

Her2-positive breast cancer: updating current best practice

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Peripheral T-Cell Lymphoma in 2013

Prolonging Progression-Free Survival in Follicular Lymphoma

Advances in Lymphoma.

Updates in Follicular Lymphoma

Treatment Decisions in Chemorefractory Follicular Lymphoma

Updates in Lymphoma From Recent Congresses

Jonathan W. Friedberg M.D., M.M.Sc.

Recent Advances in the Treatment of Lymphoma

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Knowledge Organiser – Homeostasis and the Human Nervous System

Presented By Mathias Rummel at 2016 ASCO Annual Meeting

The Road to Quality Improvement in HER2-Positive Breast Cancer

Presented By Steven Park at 2016 ASCO Annual Meeting

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Statistically Significant Cancers, Females, England,

Assessing New Paradigms in CLL: MRD Negativity

Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma by James L. Rubenstein, Huimin Geng,

Quick Lesson – Nervous System

Overall survival by SCT versus observation in first complete remission

continued on next slide

Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Andrew Evens at 2016 ASCO Annual Meeting

Changing Paradigms in Relapsed/Refractory Indolent NHL

continued on next slide

Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy Mercy Ofuya, Lucy McParland, Louise Murray,

Presentation transcript:

Presented By James Rubenstein at 2016 ASCO Annual Meeting <br /><br />Phase I Investigation of Lenalidomide plus Rituximab and Outcomes of Lenalidomide Maintenance in Recurrent CNS Lymphoma Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Key Questions Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 3 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 4 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 5 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 6 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 7 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 8 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting <br /><br /><br /><br />A Phase I Study of Lenalidomide Plus Rituximab for Recurrent/Refractory <br />Central Nervous System <br />and Intraocular Lymphoma<br /><br /><br />RV-NHL-PI-0682<br /> Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 10 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 11 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 12 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 13 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 14 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 15 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 16 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Brain Parenchymal Response<br />(20 mg Lenalidomide) Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 18 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 19 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 20 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 21 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 22 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 23 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 24 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 25 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting <br /><br />Retrospective Analysis of Maintenance After Salvage Therapy in Recurrent Disease Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 27 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 28 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 29 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 30 Presented By James Rubenstein at 2016 ASCO Annual Meeting

Presented By James Rubenstein at 2016 ASCO Annual Meeting Slide 31 Presented By James Rubenstein at 2016 ASCO Annual Meeting